title: Dihydromyricetin Reduces TGF-β Via P53 Activation-dependent Mechanism in Hepatocellular Carcinoma HepG2 Cells.
abstract: Natural antineoplastic drug development is crucial to treatment of clinical oncology. Dihydromyricetin, a bioactive flavonoid compound was extracted from the stems and leaves of Ampelopsis grossedentata. It exhibited anticancer activity and induced apoptosis in human hepatocellular carcinoma cells according to our previous studies. In this study, we demonstrated that DHM could significantly inhibit proliferation and induce apoptosis in HepG2 cells with MTT and Flow Cytometry methods. It is very interesting that we found DHM could regulate TGF-β signal pathway and which has a crosstalk with P53, Smad3 and P-Smad2/3 proteins. Meanwhile, we confirmed that DHM showed antitumor activity by regulating the activation of the p53-dependent pathways (MDM2, P-MDM2, BAX and Bcl-2). These findings defined and supported a novel mechanism that DHM could induce cell apoptosis by reducing TGF-β via p53 signal pathway in HepG2 cells.
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Huang
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease.
authors.forename: Tianming
authors.initials: T
authors.lastname: Lian
authors.affiliation: Dalian Medical University, 9 West Section, Lvshun South Road, Dalian 116044. China.
authors.forename: Xiaoqian
authors.initials: X
authors.lastname: Guan
authors.affiliation: Pharmacy College, Jinan University, Guangzhou 510632. China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease.
authors.forename: Siyuan
authors.initials: S
authors.lastname: Hao
authors.affiliation: Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001. China.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease.
authors.forename: Shiting
authors.initials: S
authors.lastname: Bao
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease.
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Tan
authors.affiliation: Laboratory of Hepatobiliary Surgery, Guangdong Medical University; Zhanjiang Key Laboratory of Hepatobiliary Disease and Clinical Research Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001. China.
authors.forename: Runzhi
authors.initials: R
authors.lastname: Zhu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D044948:Flavonols / Q000494:pharmacology*; D056945:Hep G2 Cells; D006801:Humans; D016212:Transforming Growth Factor beta / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D044948:Flavonols; C495901:TP53 protein, human; D016212:Transforming Growth Factor beta; D016159:Tumor Suppressor Protein p53; C472036:dihydromyricetin
keywords: Dihydromyricetin; P53; anti-cancer; apoptosis; hepatocellular carcinoma; proliferation